Colorectal tubulovillous adenoma

Summary

Colorectal tubulovillous adenoma (MONDO:0024662) is a cancer and 2 clinical trials. Top therapeutic interventions include sodium chloride. A subtype of colorectal adenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	colorectal tubulovillous adenoma
Mondo ID	MONDO:0024662
NCIT	C5675
UMLS	C1333118
MedGen	234165
Is cancer (heuristic)	yes

Also known as: colorectal tubulovillous adenoma · large bowel tubulovillous adenoma · tubulovillous adenoma of large bowel · tubulovillous adenoma of the large bowel

Disease family

This is a subtype of colorectal adenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm › colorectal neoplasm › colorectal adenoma › colorectal tubulovillous adenoma

Related subtypes (3): colon adenoma, rectum adenoma, colorectal sessile serrated adenoma/polyp

Subtypes (1): rectal tubulovillous adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02134925	PHASE2	ACTIVE_NOT_RECRUITING	Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
NCT01360320	PHASE2	COMPLETED	Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	1